Thyrocare Tech Peer Comparison

NSE: THYROCARE | BSE: 539871

₹501.00

₹-12.05 (-2.35%)

As on 08-Oct-2026IST

Market cap

₹7,973 Cr

Revenue (TTM)

₹876 Cr

P/E Ratio

45.2

P/B Ratio

12.7

Div. Yield

2.8 %

Edit

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Market cap (₹ Cr)	7,973	34,310	31,877	28,865	14,666
Revenue (₹ Cr)	876	4,683	2,891	4,213	857
Net Profit (₹ Cr)	174.04	552.34	546.30	190.80	187.49
Net Margin (%)	19.50	11.55	18.23	4.49	21.32
RoE (%)	32.40	14.93	23.03	9.45	20.58
Price to Earnings	45.22	61.69	58.82	141.29	78.22
Price-To-Book	12.67	8.34	12.20	7.63	14.56

Income Statement (₹ Cr)

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Operating Revenue	876.03	4,683.37	2,890.80	4,212.50	857.13
Total Income	892.52	4,783.78	2,995.90	4,248.00	879.41
Total Expenditure	594.49	3,704.62	2,053.10	3,379.70	495.19
EBITDA	281.54	978.75	837.70	832.80	361.94
Depreciation	59.66	246.41	171.60	330.60	96.06
EBIT	221.88	732.34	666.10	502.20	265.89
Interest	3.37	92.01	24.40	253.30	36.75
Other Income	16.49	100.41	105.10	35.50	22.28
Exceptional Items	-6.16	-20.61	-30.10	-11.20	0.00
Profit before Tax	228.84	720.14	716.70	273.20	251.42
Provision for Tax	54.80	167.80	170.40	82.40	63.93
Profit after Tax	174.04	552.34	546.30	190.80	187.49

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Shareholder's Funds	585.50	3,961.57	2,508.20	2,247.40	957.15
Minority Interest	0.41	3.84	-4.40	9.90	0.00
Non-Current Liabilities	51.29	1,293.60	154.00	3,961.30	426.03
Current Liabilities	109.91	627.13	450.70	1,238.90	123.87
Total Liabilities	804.51	5,905.00	3,139.97	7,690.70	1,507.05

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Non-Current Assets	300.64	3,128.95	1,176.30	5,416.90	737.24
Current Assets	372.29	1,674.92	1,566.60	937.40	321.90
Total Assets	804.51	5,905.00	3,139.97	7,690.70	1,507.05
Total Debt*	0.00	631.08	0.00	3,244.00	0.00
Net Current Assets	262.38	1,047.79	1,115.90	-301.50	198.03
Contingent Liabilities	1.86	100.01	16.76	81.10	0.13

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Cash From Operating Activities	213.24	714.39	635.61	510.80	270.59
Cash Flow from Investing Activities	-23.01	-1,089.11	-421.86	-1,451.70	-174.22
Cash from Financing Activities	-169.59	271.85	-263.57	940.30	-69.49
Net Cash Inflow / Outflow	20.64	-102.87	-49.83	-0.60	26.88

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
ROCE (%)	38.30	19.38	29.56	11.51	30.28
ROE (%)	32.40	14.93	23.03	9.45	20.58
ROA (%)	24.17	10.35	18.64	2.83	13.49
EBIT Margin (%)	25.33	15.64	23.04	11.92	31.02
Net Margin (%)	19.50	11.55	18.23	4.49	21.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Revenue Growth (%)	21.09	21.27	14.29	30.90	20.18
EBIT Growth (%)	47.74	0.94	15.64	-16.88	26.22
Net Profit Growth (%)	64.10	3.43	5.38	-52.81	24.27
EPS Growth (%)	-13.18	2.70	-30.51	-42.60	23.44
Book Value Growth (%)	6.70	16.51	15.41	5.13	21.86

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Price / Earnings	28.73	59.91	44.55	130.07	78.08
Price / Book Value	12.67	8.34	12.20	7.63	14.56
Dividend Yield (%)	2.80	0.04	1.08	0.00	0.14
EV/EBITDA	27.54	34.54	36.46	38.45	39.74
Market Cap (₹ Cr)	5,567.00	25,841.07	22,015.15	24,901.98	8,864.05

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debt to Equity	0.00	0.15	0.00	1.19	0.00
Short term debt to equity ratio	--	--	--	0.15	--
Current Ratio	3.39	2.67	3.48	0.76	2.60
Quick Ratio	2.95	2.54	3.38	0.68	2.56
Interest Coverage	68.91	8.83	30.37	2.08	7.84

	Thyrocare Tech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debtors to sales (%)	8.43	8.78	3.83	13.16	2.43
Asset Turnover	1.22	0.88	0.99	0.62	0.62
Receivable days	32.33	29.09	13.13	44.38	7.98
Inventory Days	20.91	6.05	5.28	7.52	2.20
Payable days	117.68	80.04	118.67	133.54	136.27
Cash Conversion Cycle	-64.44	-44.90	-100.26	-81.64	-126.08

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.